0001209191-23-042076.txt : 20230712
0001209191-23-042076.hdr.sgml : 20230712
20230712162754
ACCESSION NUMBER: 0001209191-23-042076
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230710
FILED AS OF DATE: 20230712
DATE AS OF CHANGE: 20230712
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cambrian BioPharma Inc
CENTRAL INDEX KEY: 0001797409
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39980
FILM NUMBER: 231084498
BUSINESS ADDRESS:
STREET 1: 228 PARK AVENUE S.
STREET 2: #66643
CITY: NEW YORK
STATE: NY
ZIP: 10003
BUSINESS PHONE: (516) 962-3186
MAIL ADDRESS:
STREET 1: 228 PARK AVENUE S.
STREET 2: #66643
CITY: NEW YORK
STATE: NY
ZIP: 10003
FORMER NAME:
FORMER CONFORMED NAME: Cambrian BioPharma Inc.
DATE OF NAME CHANGE: 20191219
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001829802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1405 RESEARCH BLVD, SUITE 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: (240) 243-8000
MAIL ADDRESS:
STREET 1: 1405 RESEARCH BLVD, SUITE 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-07-10
0
0001829802
Sensei Biotherapeutics, Inc.
SNSE
0001797409
Cambrian BioPharma Inc
19 MORRIS AVE
BROOKLYN NAVY YARD BUILDING, 128
BROOKLYN
NY
11025
0
0
1
0
0
Common Stock
2023-07-10
4
A
0
4466
0.00
A
5240422
D
Stock Option (Right to Buy)
1.22
2023-07-10
4
A
0
14550
0.00
A
2033-07-09
Common Stock
14550
14550
D
These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the James Peyer's continuous service with the Issuer through such vesting date.
These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to James Peyer's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to James Peyer's continuous service with the Issuer through such vesting date.
Cambrian BioPharma Inc, by: /s/ James Peyer
2023-07-12